Science & Technology
Clinical biomarker for early prediction of chemotherapy-induced peripheral neuropathy
Department of Health and Human Services — National Institutes of Health
Opportunity #: 1R41CA277875-01
Award Ceiling
$403K
Award Floor
$403K
Close Date
Aug 31, 2025
Total Funding
$403K
Expected Awards
1
Posted Date
Sep 19, 2023
Cost Sharing Required
No
Grants.gov ID
sbir-1R41CA277875-01
Description
STTR Phase Phase I award: "Clinical biomarker for early prediction of chemotherapy-induced peripheral neuropathy" awarded to NEWVENTUREIQ LLC in SAINT LOUIS, Missouri. Funded by Department of Health and Human Services (National Institutes of Health). Award amount: $403,240. The SBIR/STTR programs fund innovative research and development by small businesses, with Phase I for feasibility studies and Phase II for full R&D.
Eligible Applicants
Small businesses, Women-owned businesses
Apply on Grants.gov
Always verify details and apply through the official Grants.gov portal. Information here may not reflect the latest changes.
View on Grants.govDisclaimer: This information is sourced from Grants.gov and may not reflect the most current details. Always verify eligibility requirements, deadlines, and application procedures on the official program website before applying.